- Home
- LEGT vs STRO Comparison
LEGT vs STRO Comparison
Compare LEGT & STRO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LEGT
- STRO
- Stock Information
- Founded
- LEGT 2023
- STRO 2003
- Country
- LEGT United States
- STRO United States
- Employees
- LEGT N/A
- STRO N/A
- Industry
- LEGT
- STRO Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- LEGT
- STRO Health Care
- Exchange
- LEGT Nasdaq
- STRO Nasdaq
- Market Cap
- LEGT 265.3M
- STRO 292.6M
- IPO Year
- LEGT 2024
- STRO 2018
- Fundamental
- Price
- LEGT $10.29
- STRO $2.53
- Analyst Decision
- LEGT
- STRO Strong Buy
- Analyst Count
- LEGT 0
- STRO 7
- Target Price
- LEGT N/A
- STRO $12.14
- AVG Volume (30 Days)
- LEGT 37.0K
- STRO 813.4K
- Earning Date
- LEGT 01-01-0001
- STRO 11-13-2024
- Dividend Yield
- LEGT N/A
- STRO N/A
- EPS Growth
- LEGT N/A
- STRO N/A
- EPS
- LEGT N/A
- STRO N/A
- Revenue
- LEGT N/A
- STRO $160,955,000.00
- Revenue This Year
- LEGT N/A
- STRO N/A
- Revenue Next Year
- LEGT N/A
- STRO N/A
- P/E Ratio
- LEGT N/A
- STRO N/A
- Revenue Growth
- LEGT N/A
- STRO 230.90
- 52 Week Low
- LEGT $10.00
- STRO $2.13
- 52 Week High
- LEGT $10.47
- STRO $6.13
- Technical
- Relative Strength Index (RSI)
- LEGT N/A
- STRO 28.23
- Support Level
- LEGT N/A
- STRO $2.60
- Resistance Level
- LEGT N/A
- STRO $4.60
- Average True Range (ATR)
- LEGT 0.00
- STRO 0.36
- MACD
- LEGT 0.00
- STRO -0.16
- Stochastic Oscillator
- LEGT 0.00
- STRO 0.48
About LEGT Legato Merger Corp. III
Legato Merger Corp III is a blank check company.
About STRO Sutro Biopharma Inc.
Sutro Biopharma Inc is a clinical-stage drug discovery, development, and manufacturing company. It is mainly engaged in the development of biopharmaceutical products. The company manufactures next-generation protein therapeutics for cancer and autoimmune disorders through its proprietary integrated cell-free protein synthesis platform, XpressCF. Products offered by the company include STRO-001 for patients with multiple myeloma and non-Hodgkin lymphoma and STRO-002 for the treatment of ovarian and endometrial cancers.